Literature DB >> 10601837

Comparison of the effects of immunosuppressive factors from newly established colon carcinoma cell cultures on human lymphocyte proliferation and cytokine secretion.

J S Luo1, R Kammerer, S von Kleist.   

Abstract

Tumor cells may influence the host's immune reactivity by the production of immunosuppressive factors (ISFs). In this study, the effects of ISFs derived from nine polyclonal colorectal carcinoma (CRC) cell lines on PHA-induced lymphocyte proliferation and cytokine secretion was investigated. We found that most of the culture supernatants (8/9) from CRC cell lines contained ISFs, which inhibited T cell proliferation to a variable degree in a dose-dependent manner. Comparison of T cell proliferation in the presence or absence of monocytes showed that monocytes can modulate the effects of tumor-derived ISFs on lymphocyte function. In addition, exposure of activated PBMC to the tumor cell supernatants resulted in an altered secretion of cytokines by these cells, i.e. the secretion of IFN-gamma was generally reduced while the secretion of IL-1beta, IL-2 and TNF-alpha was little affected. We further investigated the supernatants' inhibitory effects on PBMC in respect to the production of prostaglandin E(2) (PGE(2)). It was found that PGE(2) was secreted by all tumor cell cultures. Therefore this substance is probably involved in the immunosuppression in vivo. However, the secreted PGE(2) was shown not to be solely responsible for the observed suppression of lymphocyte proliferation in vitro. Our results suggest that the secretion of ISF is a common property of CRCs as demonstrated with newly established CRC cell cultures, and therefore this may also be an important immune escape mechanism of colonic carcinomas in vivo. Copyright 2000 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10601837     DOI: 10.1159/000030106

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  7 in total

Review 1.  Reprogramming the tumor microenvironment: tumor-induced immunosuppressive factors paralyze T cells.

Authors:  Annie A Wu; Virginia Drake; Huai-Shiuan Huang; ShihChi Chiu; Lei Zheng
Journal:  Oncoimmunology       Date:  2015-04-01       Impact factor: 8.110

2.  Effects of cryopreservation and phenylacetate on biological characters of adherent LAK cells from patients with hepatocellular carcinoma.

Authors:  Ning Zheng; Sheng-Long Ye; Rui-Xia Sun; Yan Zhao; Zhao-You Tang
Journal:  World J Gastroenterol       Date:  2002-04       Impact factor: 5.742

3.  Cancer-associated immunodeficiency and dendritic cell abnormalities mediated by the prostaglandin EP2 receptor.

Authors:  Li Yang; Noboru Yamagata; Rajwardhan Yadav; Suzanne Brandon; Regina L Courtney; Jason D Morrow; Yu Shyr; Mark Boothby; Sebastian Joyce; David P Carbone; Richard M Breyer
Journal:  J Clin Invest       Date:  2003-03       Impact factor: 14.808

4.  Nano-scaled particles of titanium dioxide convert benign mouse fibrosarcoma cells into aggressive tumor cells.

Authors:  Kunishige Onuma; Yu Sato; Satomi Ogawara; Nobuyuki Shirasawa; Masanobu Kobayashi; Jun Yoshitake; Tetsuhiko Yoshimura; Masaaki Iigo; Junichi Fujii; Futoshi Okada
Journal:  Am J Pathol       Date:  2009-10-08       Impact factor: 4.307

5.  Soluble Fas ligand released by colon adenocarcinoma cells induces host lymphocyte apoptosis: an active mode of immune evasion in colon cancer.

Authors:  E Song; J Chen; N Ouyang; F Su; M Wang; U Heemann
Journal:  Br J Cancer       Date:  2001-09-28       Impact factor: 7.640

6.  The pattern of cytokine gene expression in human colorectal carcinoma.

Authors:  Anna Csiszár; Tamás Szentes; Bea Haraszti; Annamária Balázs; Gyôzô G Petrányi; Eva Pócsik
Journal:  Pathol Oncol Res       Date:  2004-06-09       Impact factor: 2.874

7.  Tumor and endothelial cell-derived microvesicles carry distinct CEACAMs and influence T-cell behavior.

Authors:  Harrison T Muturi; Janine D Dreesen; Elena Nilewski; Holger Jastrow; Bernd Giebel; Suleyman Ergun; Bernhard B Singer
Journal:  PLoS One       Date:  2013-09-11       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.